Strategic Considerations in Biotech M&A

The chapter explores the complexities surrounding purchase price and premiums in biotech acquisitions, addressing how stock prices can influence acquisition decisions. It delves into the challenges faced by companies with high valuations in finding buyers, and discusses the outlook for M&A in 2024, predicting increased activity due to expiring patents. The conversation emphasizes the importance of bringing valuable assets into late-stage development to attract pharma interest, and touches on the strategy of acquiring assets related to existing programs or emerging technologies.